Please assess the completion status of the following clinical trial:

Trial Title: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have a confirmed diagnosis of CD22-positive, Philadelphia chromosome (Ph)-positive or Ph-negative B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. CD22 expression will be determined by multiparameter flow cytometry (MFC) or immunohistochemistry.~* Relapsed or refractory disease, as defined by any of the following:~  * Unable to achieve complete response (CR) despite \>= 4 weeks of initial course of systemic therapy.~ * Recurrence of disease at any point after CR was achieved.~    * (Note: patients with Ph-positive disease must have received \>= 1 second- or third-generation ABL kinase inhibitor as part of their prior treatment to be eligible.)~* Detectable disease, as defined by any of the following:~  * Presence of \>= 5% abnormal blasts in the bone marrow or peripheral blood by morphology or MFC.~ * Patients with isolated extramedullary disease will be permitted if there is \>= 1 site of disease that measures \>= 1.5 cm in longest diameter on cross-sectional imaging.~* Absolute neutrophil count (ANC) \>= 1,000/uL.~* Hemoglobin \>= 8 g/dL.~* Platelets \>= 50,000/uL.~* Note: Transfusions and growth factor support will be permitted within 3 days of initiation of study treatment to reach these thresholds. As patients with relapsed/refractory ALL frequently have cytopenias due to marrow infiltration by the disease, no hematologic parameters will be required for enrollment if cytopenias can be attributed to disease.~* Total serum bilirubin =\< 1.5 x upper limit of normal (ULN); (unless due to Gilbert syndrome or hemolysis; =\< 2 x ULN for hepatic abnormalities considered disease-related).~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN.~* Serum creatinine =\< 1.5 x ULN or serum creatinine level associated with a measured or calculated creatinine clearance of \>= 40 mL/min.~* Corrected QT (QTc) interval =\< 500 msec; if assessed, left ventricular ejection fraction \>= 40%.~* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.~* Must agree to the use of effective contraception while on study treatment, unless they are highly unlikely to conceive (defined as \[1\] surgically sterilized, or \[2\] women who are and men whose sexual partner\[s\] is/are postmenopausal \[i.e., a woman who is \> 50 years old or who has not had menses for \>= 1 year\], or \[3\] not heterosexually active for the duration of the study).~Exclusion Criteria:~* Patients with a circulating blast count of \> 50,000/uL; systemic therapy with either hydroxyurea, vincristine, and/or corticosteroids will be permitted within 3 days of initiation of study treatment to reduce the blast count.~* Except for management of circulating blasts noted above, adequate duration from prior therapy must be achieved before initiation of study treatment, as defined below:~  * No cytotoxic or targeted systemic therapy \< 2 weeks or 5 half-lives (whichever is shorter).~ * No blinatumomab \< 2 weeks.~ * No radiation therapy \< 4 weeks.~ * No monoclonal antibody therapy \< 6 weeks (except for prior InO, as discussed below).~* Patients previously treated with InO will be eligible, unless they meet ANY of the following criteria:~  * \> 6 individual doses (e.g., \> 2 standard cycles) were administered.~ * Any documented hepatic toxicity observed was grade 3 or higher.~ * The most recent dose was administered \< 3 months from the initiation of study treatment.~* For patients that have received prior allogeneic HCT, they must be \>= 4 months from the date of stem cell infusion, with no prior history of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), and off all treatment for graft-vs-host disease (GVHD) for \>= 2 weeks. Patients with minimal active symptoms that can be controlled with topical therapies and/or the equivalent of prednisone =\< 10 mg/day will be eligible.~* For patients that have received other forms of cellular immunotherapy (e.g., chimeric antigen receptor-modified \[CAR\] T cells), they must be \>= 21 days from cell infusion, and any specific manifestations of cytokine release syndrome or neurologic toxicity attributable to the cellular therapy have completely resolved (i.e., \< grade 1)~* Patients with a known history of chronic liver disease, including but not limited to cirrhosis, steatohepatitis, and chronic viral hepatitis. Patients with a history of GVHD of the liver will be permitted, provided they meet all of the other eligibility criteria.~* Patients with isolated testicular or central nervous system disease.~* Known hypersensitivity or intolerance to any of the agents under investigation.~* May not be pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose -1 (0.3 mg/m^2) (Type: EXPERIMENTAL): Patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on day 8. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
- Dose 1 (0.3 mg/m^2) (Type: EXPERIMENTAL): Dose 1 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
- Dose 2 (0.6 mg/m^2, 0.3 mg/m^2) (Type: EXPERIMENTAL): Dose 2 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
- Dose 3 (0.6 mg/m^2, 0.3 mg/m^2) (Type: EXPERIMENTAL): Dose 3 patients receive etoposide, doxorubicin, and vincristine IV via continuous infusion on days 1-4, prednisone PO or IV BID on days 1-5, and cyclophosphamide IV over 1 hour on day 5. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 8 and 15. Treatment repeats approximately every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete